Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Eiichi Kumamoto
 -- 4061 2022-05-25 17:16:15 |
2 format change
Peter Tang
 -52 word(s) 4009 2022-05-26 03:13:56 | |
3 Abstract and Introduction section have been changed.
Eiichi Kumamoto
 + 89 word(s) 10312 2022-05-26 16:39:01 | |
4 format change
Peter Tang
 -131 word(s) 10181 2022-08-18 07:39:49 | |
5 format change
Peter Tang
 Meta information modification 10181 2022-08-18 10:06:16 | |
6 change to Encyclopedia Jounal entry style
Peter Tang
 -9306 word(s) 875 2022-12-01 02:34:14 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Kumamoto, E. Inhibitory Actions of Clinical Analgesics, Analgesic Adjuvants, and Plant-Derived Analgesics on Nerve Action Potential Conduction. Encyclopedia. Available online: https://encyclopedia.pub/entry/23375 (accessed on 21 December 2024).
Kumamoto E. Inhibitory Actions of Clinical Analgesics, Analgesic Adjuvants, and Plant-Derived Analgesics on Nerve Action Potential Conduction. Encyclopedia. Available at: https://encyclopedia.pub/entry/23375. Accessed December 21, 2024.
Kumamoto, Eiichi. "Inhibitory Actions of Clinical Analgesics, Analgesic Adjuvants, and Plant-Derived Analgesics on Nerve Action Potential Conduction" Encyclopedia, https://encyclopedia.pub/entry/23375 (accessed December 21, 2024).
Kumamoto, E. (2022, May 25). Inhibitory Actions of Clinical Analgesics, Analgesic Adjuvants, and Plant-Derived Analgesics on Nerve Action Potential Conduction. In Encyclopedia. https://encyclopedia.pub/entry/23375
Kumamoto, Eiichi. "Inhibitory Actions of Clinical Analgesics, Analgesic Adjuvants, and Plant-Derived Analgesics on Nerve Action Potential Conduction." Encyclopedia. Web. 25 May, 2022.
Peer Reviewed
Inhibitory Actions of Clinical Analgesics, Analgesic Adjuvants, and Plant-Derived Analgesics on Nerve Action Potential Conduction
This is a peer-reviewed entry published in Encyclopedia Journal, full entry can be found at 10.3390/encyclopedia2040132

The action potential (AP) conduction in nerve fibers plays a crucial role in transmitting nociceptive information from the periphery to the cerebral cortex. Nerve AP conduction inhibition possibly results in analgesia. It is well-known that many analgesics suppress nerve AP conduction and voltage-dependent sodium and potassium channels that are involved in producing APs. The compound action potential (CAP) recorded from a bundle of nerve fibers is a guide for knowing if analgesics affect nerve AP conduction. This entry mentions the inhibitory effects of clinically used analgesics, analgesic adjuvants, and plant-derived analgesics on fast-conducting CAPs and voltage-dependent sodium and potassium channels. The efficacies of their effects were compared among the compounds, and it was revealed that some of the compounds have similar efficacies in suppressing CAPs. It is suggested that analgesics-induced nerve AP conduction inhibition may contribute to at least a part of their analgesic effects.

antinociception analgesic analgesic adjuvant plant-derived compound nerve conduction sciatic nerve compound action potential sodium channel potassium channel
Signal of painful stimuli applied to the skin is mainly conveyed by primary-afferent thin myelinated Aδ-fibers and unmyelinated C-fibers to the spinal cord and brain stem; the information is then transmitted to the brain by the conduction of action potentials (APs) in nerve fibers and chemical transmission at neuron-to-neuron junctions [1][2][3][4]. Acute nociceptive pain caused by tissue injury or damage is a physiological mechanism that serves to protect a person against injury, which is usually alleviated by antipyretic analgesics including non-steroidal anti-inflammatory drugs (NSAIDs) and narcotic analgesics such as opioids. On the other hand, chronic pain, which may last for a long time, such as three months or more, or occur repeatedly, is a debilitating disease accompanied by spontaneous pain, etc. and is often resistant to analgesics such as NSAIDs and opioids. Neuropathic pain, which is one type of chronic pain, results from a direct injury given to the peripheral nervous system (PNS) and damage caused in the central nervous system (CNS), and it is characterized by an excessive rise in the excitability of neurons in the vicinity of injured or damaged neuronal tissues [5]. This type of pain is alleviated by using analgesic adjuvants such as local anesthetics, antiepileptics, antidepressants, and α2-adrenoceptor agonists [6][7][8][9][10][11][12][13][14][15]. Although analgesics and analgesic adjuvants generally depress excitatory synaptic transmission [16][17][18], many of their drugs can possibly suppress nerve AP conduction, which in part contributes to their inhibitory effects on pain. Plants and their constituents are used as folk remedies to relieve pain as a drug with few side effects [19][20][21].
AP conduction is produced by the activation of voltage-dependent sodium and potassium channels expressed in nerve fibers. Thus, a stimulus that induces membrane depolarization, applied to a certain point on a nerve fiber, opens a sodium channel, resulting in an influx of sodium ion into the cell according to the concentration and potential gradient across the cell membrane. This leads to AP production in a self-renewing manner, which in turn causes an outward current, i.e., membrane depolarization, to open other sodium channels at the points next to it. Such an AP production is subsided by subsequent sodium channel inactivation and potassium channel opening [22][23].

Isolation Methods for Testing Analgesic Action on Nerve Fibers

The study of AP in mammals is complicated by the need to dissect out individual nerves to isolate them from peripheral stimulation. For this reason, neuroscience relies on nerve extraction from relatively simple animals with conserved AP mechanisms, such as insects, reptiles, squids, or frogs (for example, refer to [23]).
AP current flowing on the surface of a nerve trunk consisting of many fibers can be measured as a compound action potential (CAP) by immersing the nerve in an isolator such as air, oil, or sucrose, and then by putting two electrodes on the nerve. CAPs, which are sensitive to tetrodotoxin (TTX), that blocks voltage-dependent sodium channels, and are fast-conducting (possibly mediated by primary-afferent thick myelinated Aα fibers), can be easily observed in the sciatic nerve trunk isolated from frogs by exposing the nerve trunk to air (known as the air-gap method). A half-peak duration of the CAP was increased by a voltage-dependent delayed rectifier potassium channel inhibitor, tetraethylammonium, without any alteration in its peak amplitude, which indicated that potassium channels are involved in CAP production [24]. Although the frog sciatic nerve exhibits both fast-conducting and slow-conducting (Aδ-fiber and C-fiber mediated) CAPs, the latter CAPs have much smaller peak amplitudes and conduction velocities than the former ones [25].
Fast-conducting CAPs recorded from the frog sciatic nerve were found to be inhibited by antinociceptive drugs in a manner dependent on their concentrations and chemical structures. Among the drugs, there are clinically used antinociceptive drugs including NSAIDs [26], many types of opioids such as tramadol [27][28], many amide- and ester-type local anesthetics [29], antiepileptics [30], antidepressants [31], dexmedetomidine (DEX; (+)-(S)-4-[1-(2,3-dimethylphenyl)-ethyl]-1H-imidazole, which is an α2-adrenoceptor agonist; [32]), and diverse kinds of antinociceptive compounds isolated from plants [33]. This entry will describe the effects of antinociceptive drugs on CAPs evoked in the sciatic nerves of frogs and argue how nerve AP conduction inhibitions produced by drugs differ among them. For comparison, the effects of antinociceptive drugs on peripheral nerve CAPs in mammals and voltage-dependent sodium and potassium channels that are involved in producing APs will also be mentioned, provided that data are available.

References

  1. Fields, H.L. Pain; McGraw-Hill: New York, NY, USA, 1987.
  2. Willis, W.D., Jr.; Coggeshall, R.E. Sensory Mechanisms of the Spinal Cord, 2nd ed.; Plenum: New York, NY, USA, 1991.
  3. Todd, A.J. Neuronal circuitry for pain processing in the dorsal horn. Nat. Rev. Neurosci. 2010, 11, 823–836.
  4. Merighi, A. The histology, physiology, neurochemistry and circuitry of the substantia gelatinosa Rolandi (lamina II) in mammalian spinal cord. Prog. Neurobiol. 2018, 169, 91–134.
  5. Merskey, H. Clarifying definition of neuropathic pain. Pain 2002, 96, 408–409.
  6. Amir, R.; Argoff, C.E.; Bennett, G.J.; Cummins, T.R.; Durieux, M.E.; Gerner, P.; Gold, M.S.; Porreca, F.; Strichartz, G.R. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain 2006, 7, S1–S29.
  7. Finnerup, N.B.; Sindrup, S.H.; Jensen, T.S. The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150, 573–581.
  8. Jensen, T.S. Anticonvulsants in neuropathic pain: Rationale and clinical evidence. Eur. J. Pain 2002, 6, 61–68.
  9. Kamibayashi, T.; Maze, M. Clinical uses of α2-adrenergic agonists. Anesthesiology 2000, 93, 1345–1349.
  10. Lynch, M.E. Antidepressants as analgesics: A review of randomized controlled trials. J. Psychiatry Neurosci. 2001, 26, 30–36.
  11. Sindrup, S.H.; Otto, M.; Finnerup, N.B.; Jensen, T.S. Antidepressants in the treatment of neuropathic pain. Basic Clin. Pharmacol. Toxicol. 2005, 96, 399–409.
  12. Theile, J.W.; Cummins, T.R. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front. Pharmacol. 2011, 2, 54.
  13. Waszkielewicz, A.M.; Gunia, A.; Słoczyńska, K.; Marona, H. Evaluation of anticonvulsants for possible use in neuropathic pain. Curr. Med. Chem. 2011, 18, 4344–4358.
  14. Fakhri, S.; Abbaszadeh, F.; Jorjani, M. On the therapeutic targets and pharmacological treatments for pain relief following spinal cord injury: A mechanistic review. Biomed. Pharmacother. 2021, 139, 111563.
  15. Kocot-Kępska, M.; Zajączkowska, R.; Mika, J.; Kopsky, D.J.; Wordliczek, J.; Dobrogowski, J.; Przeklasa-Muszyńska, A. Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain—Narrative review. Pharmaceutics 2021, 13, 450.
  16. Fürst, S. Transmitters involved in antinociception in the spinal cord. Brain Res. Bull. 1999, 48, 129–141.
  17. Kumamoto, E. Cellular mechanisms for antinociception produced by oxytocin and orexins in the rat spinal lamina II—Comparison with those of other endogenous pain modulators. Pharmaceuticals 2019, 12, 136.
  18. Zeilhofer, H.U.; Wildner, H.; Yévenes, G.E. Fast synaptic inhibition in spinal sensory processing and pain control. Physiol. Rev. 2012, 92, 193–235.
  19. Gouveia, D.N.; Pina, L.T.S.; Rabelo, T.K.; da Rocha Santos, W.B.; Quintans, J.S.S.; Guimarães, A.G. Monoterpenes as perspective to chronic pain management: A systematic review. Curr. Drug Targets 2018, 19, 960–972.
  20. Wang, Z.-J.; Heinbockel, T. Essential oils and their constituents targeting the GABAergic system and sodium channels as treatment of neurological diseases. Molecules 2018, 23, 1061.
  21. Gouveia, D.N.; Guimarães, A.G.; da Rocha Santos, W.B.; Quintans-Júnior, L.J. Natural products as a perspective for cancer pain management: A systematic review. Phytomedicine 2019, 58, 152766.
  22. Kiernan, M.C.; Bostock, H.; Park, S.B.; Kaji, R.; Krarup, C.; Krishnan, A.V.; Kuwabara, S.; Lin, C.S.; Misawa, S.; Moldovan, M.; et al. Measurement of axonal excitability: Consensus guidelines. Clin. Neurophysiol. 2020, 131, 308–323.
  23. Levitan, I.B.; Karczmarek, L.K. The Neuron, 3rd ed.; Oxford University Press: New York, NY, USA, 2002.
  24. Kumamoto, E.; Mizuta, K.; Fujita, T. Peripheral nervous system in the frog as a tool to examine the regulation of the transmission of neuronal information. In Frogs: Biology, Ecology and Uses; Murray, J.L., Ed.; Nova Science Publishers, Inc.: New York, NY, USA, 2012; pp. 89–106.
  25. Kobayashi, J.; Ohta, M.; Terada, Y. C fiber generates a slow Na+ spike in the frog sciatic nerve. Neurosci. Lett. 1993, 162, 93–96.
  26. Suzuki, R.; Fujita, T.; Mizuta, K.; Kumamoto, E. Inhibition by non-steroidal anti-inflammatory drugs of compound action potentials in frog sciatic nerve fibers. Biomed. Pharmacother. 2018, 103, 326–335.
  27. Katsuki, R.; Fujita, T.; Koga, A.; Liu, T.; Nakatsuka, T.; Nakashima, M.; Kumamoto, E. Tramadol, but not its major metabolite (mono-O-demethyl tramadol) depresses compound action potentials in frog sciatic nerves. Br. J. Pharmacol. 2006, 149, 319–327.
  28. Mizuta, K.; Fujita, T.; Nakatsuka, T.; Kumamoto, E. Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures. Life Sci. 2008, 83, 198–207.
  29. Magori, N.; Fujita, T.; Mizuta, K.; Kumamoto, E. Inhibition by general anesthetic propofol of compound action potentials in the frog sciatic nerve and its chemical structure. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2019, 392, 359–369.
  30. Uemura, Y.; Fujita, T.; Ohtsubo, S.; Hirakawa, N.; Sakaguchi, Y.; Kumamoto, E. Effects of various antiepileptics used to alleviate neuropathic pain on compound action potential in frog sciatic nerves: Comparison with those of local anesthetics. Biomed. Res. Int. 2014, 2014, 540238.
  31. Hirao, R.; Fujita, T.; Sakai, A.; Kumamoto, E. Compound action potential inhibition produced by various antidepressants in the frog sciatic nerve. Eur. J. Pharmacol. 2018, 819, 122–128.
  32. Kosugi, T.; Mizuta, K.; Fujita, T.; Nakashima, M.; Kumamoto, E. High concentrations of dexmedetomidine inhibit compound action potentials in frog sciatic nerves without α2 adrenoceptor activation. Br. J. Pharmacol. 2010, 160, 1662–1676.
  33. Kumamoto, E. Effects of plant-derived compounds on excitatory synaptic transmission and nerve conduction in the nervous system—Involvement in pain modulation. Curr. Top. Phytochem. 2018, 14, 45–70.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Eiichi Kumamoto
View Times: 797
Entry Collection: Biopharmaceuticals Technology
Online Date: 25 May 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback